Clinical Trials Browser

zimberelimab × 30 days × Clear all

NCT06532565 2026-04-21

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT04656535 2026-04-17

AB154 Combined With AB122 for Recurrent Glioblastoma

Phase EARLY_PHASE1 Active not recruiting

Glioblastoma, Recurrence

NCT06082960 2026-04-16

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT05568095 2026-04-02

STAR-221

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04104672 2026-03-31

ARC-8

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05130177 2026-03-31

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Phase 2 Active not recruiting

Melanoma

NCT05891171 2026-03-31

ARC-25

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04736173 2026-03-30

ARC-10

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05329766 2026-03-30

EDGE-Gastric

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05536141 2026-03-30

ARC-20

Phase 1 Recruiting

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms